Patent · US Active

Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors

US8883801B2 · kind B2 · utility

1Cited by

5References

13Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Lianyun Zhao · Burlington, US
Duan Liu · Arlington, US
Shuyi Tang · Shanghai, CN
Amit K. Mandal · Shrewsbury, US
Umar Faruk Mansoor · Framingham, US
Lalanthi Dilrukshi Vitharana · Somerville, US
Panduranga Adulla P. Reddy · Walpole, US
M. Arshad Siddiqui · Newton, US

Key dates

Filing date	Aug 22, 2011
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Aug 22, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I)as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.